George Scangos, Ph.D., served as the CEO of Vir Biotechnology, Inc. from January 2020 until April 2023, when he stepped down after a successful run. Dr. Scangos holds a Ph.D. in Biochemistry from the University of California, San Francisco, bringing...

George Scangos, Ph.D., served as the CEO of Vir Biotechnology, Inc. from January 2020 until April 2023, when he stepped down after a successful run. Dr. Scangos holds a Ph.D. in Biochemistry from the University of California, San Francisco, bringing a strong scientific background to his leadership role in biotechnology. Under his guidance, the company intensified its focus on developing treatments and preventative options for infectious diseases, including COVID-19. For instance, they expanded their operations significantly during the pandemic and delivered around 1.5 million doses of their leading drug, sotrovimab, which generated over $1.5 billion in collaboration revenue. Scangos is known for aligning the company’s research objectives with pressing public health needs. His annual compensation varied widely, peaking at nearly $20.7 million in 2021, reflecting both stock and performance-based incentives. Notably, he transitioned the company’s business strategy to focus on SARS-CoV-2, which represented a major pivot in their operations during his tenure. George’s career highlights the importance of blending scientific expertise with strategic leadership in the biotechnology field, making notable contributions to advancing therapies for serious diseases.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Vir Biotechnology, Inc. CEOs

V

George Scangos, Ph.D.

Ex-CEO of Vir Biotechnology, Inc.

Education

Ph.D. in Biochemistry from the University of California, San Francisco.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

June 9, 1958 - 66 years ago

CEO of Vir Biotechnology, Inc. for

3 years 2 months (Jan 2020 - Apr 2023)

Previous Experience

Former CEO of several biopharmaceutical companies, including Aileron Therapeutics and BioMarin Pharmaceutical.

Rivals

Competitors/colleagues of George Scangos, Ph.D.

Holdings

See how much did George Scangos, Ph.D. make over time.

As of early 2023, George Scangos held 6.98 million shares in Vir Biotechnology, which represents about 6.3% of the company. Over the years, his stock holdings have fluctuated significantly due to stock options and performance-based grants. In 2022, he had...

As of early 2023, George Scangos held 6.98 million shares in Vir Biotechnology, which represents about 6.3% of the company. Over the years, his stock holdings have fluctuated significantly due to stock options and performance-based grants. In 2022, he had most of his wealth tied to these holdings, seeing a peak compensation of nearly $20.7 million demonstrating a strong alignment between his performance and the company's financial success. His stock vested annually, including 111,000 restricted stock units in 2022, showcasing a commitment to long-term growth in the firm’s share value. This strategic ownership structure not only motivated him but also engendered confidence among investors, reflecting how executive ownership can directly correlate with company performance.

Mar 18, 2025

V

shares

VIR @ $6.93

Insider Trading

See recent insider trades of George Scangos, Ph.D..

No insider trades found for this CEO.

Compensation History

See how much did George Scangos, Ph.D. make over time.

During his tenure as CEO, George Scangos's compensation changed significantly based on his performance and company success. In 2023, he earned $1.8 million, which included a $325,000 salary and a sizeable stock vesting totaling around $1.46 million in value. His compensation peaked in 2021 at almost $20.7 million, mainly due to stock options and performance bonuses. The structure of his pay reflects the company's success and his strategic decisions, with a focus on long-term incentives. His salary increased over the years, driven by his impactful leadership during crucial times, particularly in navigating the challenges posed by the COVID-19 pandemic. Scangos's compensation package underscores the intertwining of executive pay with company performance, aiming to attract top talent while motivating them to achieve set objectives.

Year

2023

Total Compensation

$1.80M

Salary

$325.00K

Board Justification

The compensation philosophy emphasizes alignment with company performance and retention of key executives during transitions.

Bonus

$0.00

Board Justification

Not eligible for payouts under the 2023 annual incentive plan due to the timing of departure.

Other

$13.20K

Board Justification

Includes matching contributions made under the 401(k) plan.

Restricted Stock

$1.46M(55K RSU)

Board Justification

55,000 shares of common stock vested in 2023 as part of his compensation package.

Performance Metrics

Not applicable as he was not eligible for performance-based compensation in 2023.

Other Vir Biotechnology, Inc. CEOs

Here are other CEOs of Vir Biotechnology, Inc.

Marianne De Backer, MSc, Ph.D., MBA

CEO of Vir Biotechnology, Inc.

April 2023 - Present